Apoptosis induced by molecular targeting therapy in hematological malignancies

Acta Haematologica

Volumn 111, Issue 1-2, 2004, Pages 107-123

  Adachi, Souichi ^a   Leoni, Lorenzo M ^c   Carson, Dennis A ^b   Nakahata, Tatsutoshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Salmedix Inc   (United States)

Author keywords

Anti CD20; Anti CD33; Apoptosis; Arsenic trioxide; Etodolac; FLT3 inhibitor; Imatinib mesylate; Molecular targeting therapy

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENDAMUSTINE; CARBAZOLE DERIVATIVE; CD20 ANTIGEN; CEP 701; CYTARABINE; ETODOLAC; FLT3 LIGAND INHIBITOR; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; RAS PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RITUXIMAB; SDX 101; SEMAXANIB; STAT5 PROTEIN; STAUROSPORINE DERIVATIVE; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; APOPTOSIS; B LYMPHOCYTE; CARDIOTOXICITY; CELL LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; REVIEW; SKIN MANIFESTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 0345059960     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074490     Document Type: Review

References (141)

1. Deninger MWN, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
4. Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Resta D, Capdeville R, Druker B: Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia (abstract). Blood 2000;96:470.
5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ben-Am M, Capdeville R, Druker B: A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis (abstract). Blood 2000;96:503.
6. Talpaz M, Silver RT, Druker B, Paquette R, Goldman JM, Reese SF, Capdeville R: A phase II study of STI571 in adults patients with Philadelphia chromosome-positive chronic myeloid leukemia in accelerated phase (abstract). Blood 2000;96:469.
7. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fisher T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fermandes-Reese S, Gathmann I, Capdeville R, O'Brien SG: A phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-1971.
8. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic mylogenous leukemia in blast phase. Blood 2002;99: 3547-3553.
9. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
10. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of haematopoitic progenitor cells in chronic myeloid leukemia. Nature 1987;328:342-344.
11. Puil L, Liu J, Gish G Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signaling pathway. EMBO J 1994;13:764-773.
12. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83: 2038-2044.
13. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM: Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J Clin Invest 1994;94:384-391.
14. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV: BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000;60:2049-2055.
15. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y, Takai E, Mizuki M, Machi T, Wakao H, Kanakura Y: Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002;277:8076-8082.
16. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/ M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995;86: 1148-1158.
17. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E: BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998;91:2415-2422.
18. Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K: Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-1705.
19. Sanchez Garcia I, Martin Zanca D: Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 1997;267:225-228.
20. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B: Transformation of hematopoietic cells by BCR/ABL required activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-6161.
21. Horita M, Andreu EJ, Benito A: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-984.
22. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD: STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-2125.
23. Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
24. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998;4:1661-1672.
25. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ ABL(+)leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-394.
26. Dan S, Naito M, Tsuruo T: Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998;5:710-715.
27. Fang G, Kim CN, Perkins CL, Ramadevl N, Winton E, Wittmann S, Bhala KN: CGP571448B (STI571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to anti-leukemic drugs. Blood 2000;96:2246-2253.
28. Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH: Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002;99:664-671.
29. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
30. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928-1937.
31. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002;99:3530-3539.
32. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99: 3547-3553.
33. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME: Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002;100: 435-441.
34. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590-1595.
35. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, Magenis E, Capdeville R, Druker BJ: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628-1633.
36. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-1971.
37. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
38. Nimmanapalli R, Bhalla K: Novel targeted therapies for Bcr-Abl positive acute leukemias: Beyond STI571. Oncogene 2002;21:8584-8590.
39. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers L: The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15: 1537-1543
40. Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000;95:1014-1022.
41. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agants against Bcr-Abl-positive cells. Blood 2000;96:3195-3199.
42. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002;62:188-199.
43. Nakajima A, Tauchi T, Sumi M, Bishop RW, Ohyashiki K: Efficacy of SCH66336, the farnesyl transferase inhibitor, against Gleevec-resistant BCR-ABL-positive cells (abstract). Proc Am Assoc Cancer Res 2002;43:855.
44. Mow BMF, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH: Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002;99:664-671.
45. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-3274.
46. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90: 2188-2195.
47. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
48. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-661.
49. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PWM, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZS, Lister TA: A UK multicentre phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma with PCR monitoring of molecular response. Br J Haematol 2000;109:81-88.
50. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857.
51. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Deiwall V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Manthieu-Boue A, Sola-Celigny P: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001;97:101-106.
52. Hainsworth JD, Burris HA III, Morrissey LH, Litchy S, Scuillin DC Jr, Bearrden JD III, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 2000;95:3052-3056.
53. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste EVD, Salles G, Gaulard P, Reyes F, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
54. Czuczman MS, Jonas C, Stephan M, Scarpace A, Rock M, Kunkel L, Grillo-Lopez A, Bernstein SH: Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma (abstract). Proc Am Soc Clin Oncol 1999;18:17.
55. Weide R, Heymanns J, Gores A, Koppler H: Bendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymph 2002;43:327-331.
56. Maloney DG, Smith B, Rose A: Rituximab: Mechanism of action and resistance. Semin Oncol 2002;2:2-9.
57. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91: 1644-1652.
58. Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y: Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998;89:748-756.
59. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I: Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000;204: 55-63.
60. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY: Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Res 2000; 60:7170-7176.
61. Hofmeister JK, Cooney D, Coggeshall KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phos-phorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000;26:133-143.
62. Ghetie MA, Bright H, Vitetta ES: Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97: 1392-1398.
63. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G: Binding to CD20 by anti-B1 antibody or F(ab))2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24.
64. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cell lines through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99: 1314-1319.
65. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-1043.
66. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA, Ledbetter JA: Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-γ 1 and PLC phospholipase C-γ 2. J Immunol 1993; 151:4494-4504.
67. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673-683.
68. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P: Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn and Lck with the B-cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995;270: 22632-22638.
69. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: Signaling through lipid rafts. Immunology 2002;107:176-182.
70. Van der Kolk LE, Evers LM, Omene C, Lens SMA, Lederman S, van Lier RAW, van Oers MHJ, Eldering E: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002;16:1735-1744.
71. Ghetie MA, Bright H, Vitetta ES: Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97: 1392-1398.
72. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186.
73. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and ri-tuximab. Anticancer Res 2000;20:2961-2966.
74. Alas S, Emmanouillides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-723.
75. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-5144.
76. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement and caspases. Haematologica 2002;87:33-43.
77. Alas S, Ng CP, Bonavida B: Rituximab modifies the cisplatin- mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:836-845.
78. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999;341: 1051-1062.
79. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986;67:1048-1053.
80. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-534.
81. Peiper SC, Ashmun RA, Look AT: Molecular cloning, expression and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 1988;72: 314-321.
82. Van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJM: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg 8CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197-3204.
83. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID: Selective ablation of acute using antibody-targeted chemotherapy: A phase I study of anti-CD33 cali-cheamicin immunoconjugate. Blood 1999;93: 3678-3684.
84. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Benett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-3254.
85. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID: Multi-drug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-994.
86. Zein N, Sinha AM, McGahren WJ, Ellestad GA: Calicheamicin γ 1:An antitumor antibiotic that cleaves double-stranded DNA site specificity. Science 1988;240:1198-1201.
87. Nicolaou KC, Smith AL, Yue EW: Chemistry and biology of natural and designed enediynes. Proc Natl Acad Sci USA 1993;90:5881-5888.
88. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J: Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin (Mylotarg) in vitro. Role of chk1 and chk2 phosphorylation and caspase 3. Blood 2003;101:4589-4597/Epub Feb 6, 2003.
89. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP: FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001:97;3589-3595.
90. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP: Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:3689-3595.
91. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT: FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 2000;111:190-195.
92. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT: Sustained in vivo regression of Dunning H rat prostate cancers treated combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999;59:2395-2401.
93. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.
94. Weisberg E, Boulton Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1:433-443.
95. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59: 99-106.
96. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA: CT53518, a novel selective FLT3 antagonist for the treatment of acute mylogenous leukemia. Cancer Cell 2002;1:421-432.
97. Propper DJ, McDonald AC, Man A, Thavasu P, Balkw F III, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-1492.
98. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T: Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-631.
99. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99:3885-3891.
100. Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, Schubiger PA, Bodis S, Pruschy M: The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 2001;61:8203-8210.
101. Rocha S, Soengas MS, Lowe SW, Glanzmann C, Fabbro D, Winterhalter K, Bodis S, Pruschy M: Protein kinase C inhibitor and irradiation-induced apoptosis: Relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ 2000;11:491-499.
102. Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W: The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003;101:1494-1504.
103. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605.
104. Borrow J, Goddard AD, Sheer D, Solomon E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-1580.
105. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP Jr: All-trans-retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997;40(suppl): 25-29.
106. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
107. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood1990;76:1704-1709.
108. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-1393.
109. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860.
110. Cheson BD: Hematologic malignancies: New developments and future treatments. Semin Oncol 2002;29(suppl 13):33-45.
111. 3 (exerts dose-dependent dual effects on APL cells. Blood 1997;89: 3345-3353.
112. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Coco FL, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. Natl Cancer Inst 1998;90:124-133.
113. 4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML/RARα proteins. Blood 1996;88: 1052-1061.
114. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
115. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelo-cytic leukemia. Leukemia 2000;14:262-270.
116. Chen YH, Lin-Shiau SY, Lin JK: Involvement of reactive oxygen species and caspase-3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-333.
117. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G: Arsenite induces via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249: 413-421.
118. Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, Montserrat E, Pons G, Gill J: Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998;92:1406-1414.
119. Klampfer L., Cammenga J, Wisniewski HG, Nimer SD: Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999;93:2386-2394.
120. Shiff SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
121. Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and antineoplastic actions of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclooxy-genase-null embryo fibroblasts. J Exp Med 1999;90:451-459.
122. Shiff SJ, Rigas B: The role of cyclooxygenase inhibition in the antineoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs). J Exp Med 1999;190:445-450.
123. Cronstein BN, Montesinos MC, Weissmann G: Salicylates and sulfasalazine, but not glu-cocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of
124. Martens ME, Chang CH, Lee CP: Reye's syndrome: Mitochondrial swelling and Ca(2+)release induced by Reye's plasma, allantoin and salicylate. Arch Biochem Biophys 1986;244: 773-786.
125. Tomoda T, Takeda K, Kurashige T, Enzan H, Miyahara M: Acetylsalicylate-induced mitochondrial dysfunction and its potentiation by Ca(2+). Liver 1994;14:103-108.
126. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-3410.
127. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najih J: Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-25580.
128. Moon EY, Lerner A: Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711-5719.
129. Brocks DR, Jamali F: Etodolac clinical pharmacokinetics. Clin Pharmacokinet 1994;26: 259-274.
130. Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C: Resolution of etodolac and anti-inflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 1983; 26:1778-1780.
131. Nardella FA, LeFevre JA: Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Arthritis Rheum 1999;42:S56.
132. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF: Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-350.
133. Leoni, LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, Budihardjo I, Wang X, Carson DA: Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA 1998;95: 9567-9571.
134. Gottlieb R, Adachi S: Nitrogen cavitation for cell disruption to obtain mitochondria from cultured cells. Methods Enzymol 2000;322: 213-221.
135. Adachi S, Cross AR, Babior BM, Gottlieb RA: Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. J Biol Chem 1997;272:21878-21882.
136. Leoni LM, Adachi S, Tawatao RI, Kitada S, Welch J, Genini D, Cottam HB, Gottlieb RA, Glass CK, Kippe TJ, Reed JC, Carson DA: Induction of apoptosis in chronic lymphocytic leukemia and multiple myeloma cells by R-etodolac. Leuk Lymphoma 2001;42(suppl 1):49.
137. Kitada S, Anderson J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlation with in vivo and in vitro resistance. Blood 1998;91:3379-3389.
138. Adachi S, Amox DG, Kitada S, Carson DA, Leoni LM: Etodolac: A nonsteroidal anti-inflammatory drug that induces apoptosis in B-cell chronic lymphocytic leukemia cells in vitro and in vivo (abstract). Proc Am Assoc Cancer Res 2000;41:739.
139. Vane JR, Bakhle YS, Botting RM: Cyclooxy-genases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
140. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
141. Leoni LM, Carson DA, Scranton S, Rosenthal AS: In vitro and in vivo activity of SDX-101 (R-etodolac), a pro-apoptotic compound for the treatment of chronic lymphocytic leukemia, multiple myeloma and lymphoma (abstract). Ann Oncol 2002;13: